SG11201901584UA - Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof - Google Patents

Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof

Info

Publication number
SG11201901584UA
SG11201901584UA SG11201901584UA SG11201901584UA SG11201901584UA SG 11201901584U A SG11201901584U A SG 11201901584UA SG 11201901584U A SG11201901584U A SG 11201901584UA SG 11201901584U A SG11201901584U A SG 11201901584UA SG 11201901584U A SG11201901584U A SG 11201901584UA
Authority
SG
Singapore
Prior art keywords
monoclonal antibody
pharmaceutical composition
pdl
seq
amino acid
Prior art date
Application number
SG11201901584UA
Other languages
English (en)
Inventor
Baiyong Li
Yu Xia
Zhongmin Maxwell Wang
Peng Zhang
Original Assignee
Akeso Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akeso Biopharma Inc filed Critical Akeso Biopharma Inc
Publication of SG11201901584UA publication Critical patent/SG11201901584UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7019—Ischaemia
SG11201901584UA 2016-08-23 2017-08-22 Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof SG11201901584UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610705763.5A CN106977602B (zh) 2016-08-23 2016-08-23 一种抗pd1单克隆抗体、其药物组合物及其用途
PCT/CN2017/098465 WO2018036472A1 (fr) 2016-08-23 2017-08-22 Anticorps monoclonal anti-pd-1, composition pharmaceutique et utilisation de celui-ci

Publications (1)

Publication Number Publication Date
SG11201901584UA true SG11201901584UA (en) 2019-03-28

Family

ID=59340342

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901584UA SG11201901584UA (en) 2016-08-23 2017-08-22 Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof

Country Status (15)

Country Link
US (1) US20190321466A1 (fr)
EP (1) EP3505535A4 (fr)
JP (1) JP7082620B2 (fr)
KR (1) KR102469286B1 (fr)
CN (1) CN106977602B (fr)
AU (1) AU2017316255B2 (fr)
BR (1) BR112019003775A2 (fr)
CA (1) CA3034849A1 (fr)
EA (1) EA201990570A1 (fr)
IL (1) IL264956B2 (fr)
MX (1) MX2019002268A (fr)
NZ (1) NZ751902A (fr)
SG (1) SG11201901584UA (fr)
WO (1) WO2018036472A1 (fr)
ZA (1) ZA201901781B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2978942A1 (fr) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procedes d'utilisation
EP3322732A2 (fr) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc. Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
WO2018035710A1 (fr) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anticorps anti-ctla4
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CN106977602B (zh) * 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
WO2018222949A1 (fr) 2017-06-01 2018-12-06 Cytomx Therapeutics, Inc. Anticorps anti-pdl1 activables, et leurs procédés d'utilisation
CN109425736B (zh) * 2017-08-25 2021-04-09 北京百普赛斯生物科技股份有限公司 一种检测pd-1抗体血药浓度的方法及试剂盒
CA3075927A1 (fr) * 2017-09-20 2019-03-28 Regeneron Pharmaceuticals, Inc. Procedes d'immunotherapie pour des patients dont les tumeurs transportent une charge de mutation de gene passager elevee
US20210363255A1 (en) * 2018-04-04 2021-11-25 Truebinding, Inc. Methods and compositions for blocking interaction between non-glycosylated pd-1 polypeptides
IL307925A (en) 2018-05-07 2023-12-01 Genmab As Combination of an antibody against 1-PD and conjugation of a drug with an antibody against TF for use in the treatment of cancer
US20220160700A1 (en) * 2018-07-18 2022-05-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Therapeutic combination of quinoline derivative and antibody
CN109053889B (zh) * 2018-07-25 2019-06-21 博奥信生物技术（南京）有限公司 一种抗人pd1单克隆抗体及用途
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
EP3946377A1 (fr) 2019-04-03 2022-02-09 Orega Biotech Polythérapies basées sur des inhibiteurs de pd1 et il-17 b
CN110373415B (zh) * 2019-06-12 2023-06-09 安徽省昂普拓迈生物科技有限责任公司 特异性结合pd-l1蛋白的核酸适配体及其用途
JP6881658B2 (ja) 2019-07-05 2021-06-02 小野薬品工業株式会社 Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
AU2020324185A1 (en) * 2019-08-02 2022-03-03 CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. Anti-PD-1 antibody and medical use thereof
US20220332825A1 (en) 2019-08-08 2022-10-20 Ono Pharmaceutical Co., Ltd. Bispecific protein
CN110903391B (zh) * 2019-10-25 2021-05-28 东大生物技术(苏州)有限公司 一组pd-l1单克隆抗体及其医药用途
WO2021121373A1 (fr) * 2019-12-20 2021-06-24 广东菲鹏制药股份有限公司 Anticorps monoclonal anti-mort programmée humaine (pd-1)
JP2023514957A (ja) 2020-02-28 2023-04-12 オレガ・バイオテック Ｃｔｌａ４阻害剤及びｉｌ－１７ｂ阻害剤に基づく複合療法
CA3176321A1 (fr) * 2020-04-22 2021-10-28 Peng Zhang Anticorps bispecifique anti-cd73-anti-pd-1 et son utilisation
AU2021263650A1 (en) 2020-04-29 2023-01-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bifunctional protein against PD-1 and TGF-beta
CN113754767A (zh) * 2020-06-03 2021-12-07 上海恒润达生生物科技股份有限公司 抗人pd-1抗体及其用途
CN114761434B (zh) * 2020-09-30 2023-06-27 苏州沙砾生物科技有限公司 Pd-1抗体及其制备方法与应用
JP2023549581A (ja) 2020-11-17 2023-11-27 シージェン インコーポレイテッド ツカチニブ及び抗ｐｄ－１／抗ｐｄ－ｌ１抗体の組み合わせによりがんを治療する方法
CN113336848B (zh) * 2021-02-03 2022-08-19 上海莱馥医疗科技有限公司 一种抗pd-1抗体及其用途
KR20240046323A (ko) 2021-07-13 2024-04-08 비온테크 에스이 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제
CA3233205A1 (fr) 2021-09-29 2023-04-06 Yu Xia Anticorps anti-lag3, composition pharmaceutique et utilisation
CA3234647A1 (fr) 2021-10-06 2023-04-13 Genmab A/S Agents de liaison multispecifiques diriges contre pd-l1 et cd137 en combinaison
WO2023083439A1 (fr) 2021-11-09 2023-05-19 BioNTech SE Agoniste de tlr7 et combinaisons pour le traitement du cancer
CN113912710B (zh) * 2021-11-17 2023-05-26 杭州旭科生物技术有限公司 抗新型冠状病毒n蛋白的单克隆抗体及其应用
EP4257609A1 (fr) 2022-04-08 2023-10-11 iOmx Therapeutics AG Polythérapies à base d'inhibiteurs de pd-1 et de sik3
WO2023198060A1 (fr) * 2022-04-12 2023-10-19 正大天晴药业集团股份有限公司 Association pharmaceutique d'inhibiteur de protéasome et d'anticorps anti-pd-1
WO2023217987A1 (fr) * 2022-05-12 2023-11-16 BioNTech SE Anticorps monoclonaux dirigés contre la protéine de mort programmée 1 et leur utilisation en médecine
WO2023218046A1 (fr) 2022-05-12 2023-11-16 Genmab A/S Agents de liaison capables de se lier à cd27 en polythérapie
WO2023217268A1 (fr) * 2022-05-13 2023-11-16 正大天晴药业集团南京顺欣制药有限公司 Combinaison médicamenteuse d'anticorps anti-tim-3 et d'anticorps anti-pd-1
WO2024051670A1 (fr) * 2022-09-06 2024-03-14 正大天晴药业集团股份有限公司 Combinaison pharmaceutique d'anticorps se liant à tim-3 et d'anticorps se liant à pd-1
WO2024077069A1 (fr) * 2022-10-05 2024-04-11 Chulalongkorn University Anticorps monoclonaux dirigés contre la protéine 1 de mort cellulaire programmée humaine (pd-1)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CN101899114A (zh) * 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
CA2970873C (fr) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d'autres immunotherapies
AU2009296392B2 (en) * 2008-09-26 2016-06-02 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
TR201810298T4 (tr) * 2011-03-31 2018-08-27 Merck Sharp & Dohme İnsan programlı ölüm reseptörü PD-1'e karşı antikorların stabil formülasyonları ve ilgili tedaviler.
CA2833636A1 (fr) * 2011-04-20 2012-10-26 Amplimmune, Inc. Anticorps et autres molecules qui se lient a b7-h1 et a pd-1
ES2848052T3 (es) * 2012-08-03 2021-08-05 Dana Farber Cancer Inst Inc Anticuerpos de unión dual anti-PD-L1 y PD-L2 de agente individual y métodos de uso
CN104250302B (zh) * 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
CR20160319A (es) * 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CN105175544B (zh) 2015-10-20 2021-04-09 安徽瀚海博兴生物技术有限公司 一种抗pd-1人源化单克隆抗体及其应用
CN105175545B (zh) * 2015-10-20 2019-01-25 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd-1双功能抗体及其应用
CN106977602B (zh) * 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
CN106967172B (zh) * 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途

Also Published As

Publication number Publication date
AU2017316255B2 (en) 2024-02-01
CN106977602B (zh) 2018-09-25
EP3505535A4 (fr) 2020-04-15
EA201990570A1 (ru) 2019-08-30
US20190321466A1 (en) 2019-10-24
IL264956B2 (en) 2023-04-01
CN106977602A (zh) 2017-07-25
EP3505535A1 (fr) 2019-07-03
JP2019534034A (ja) 2019-11-28
MX2019002268A (es) 2019-10-21
KR20190050994A (ko) 2019-05-14
AU2017316255A1 (en) 2019-04-11
WO2018036472A1 (fr) 2018-03-01
NZ751902A (en) 2022-05-27
KR102469286B1 (ko) 2022-11-22
CA3034849A1 (fr) 2018-03-01
BR112019003775A2 (pt) 2019-06-25
ZA201901781B (en) 2023-10-25
IL264956A (en) 2022-12-01
JP7082620B2 (ja) 2022-06-08

Similar Documents

Publication Publication Date Title
SG11201901584UA (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
MY192822A (en) An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use
NZ717213A (en) Anti-pd-l1 antibodies and their use to enhance t-cell function
MY187741A (en) Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
PH12014501783B1 (en) Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
NZ612055A (en) Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib
NZ706004A (en) Antibodies for treatment of cancer expressing claudin 6
NZ605980A (en) Anti-fap antibodies and methods of use
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
NZ630433A (en) Antibodies and uses thereof to detect folate receptor 1
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2014012085A3 (fr) Hétérodimères asymétriques bispécifiques comprenant des produits de recombinaison anti-cd3
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
NZ700473A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
NZ626269A (en) Anti-phf-tau antibodies and their uses
NZ595464A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
NZ586053A (en) Anti-vegf antibody compositions and methods
MX2021001672A (es) Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car.
MY196874A (en) Humanized anti-basigin antibodies and the use thereof
ES2684173T3 (es) Anticuerpos anti-XCR1 humano
MX2016008520A (es) Anticuerpo bdca-2 antihumano novedoso.
MY181914A (en) Novel anti-human ig? antibody